← Back to Search

Other

Mail-In Semen Analysis Kit for Male Infertility (EXPLORE Trial)

N/A
Recruiting
Led By Yanett Anaya, M.D.
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All English or Spanish speaking male partners of female patients undergoing an infertility work-up evaluation at Zuckerberg San Francisco General Hospital and recommended to undergo a semen analysis as a part of this workup.
Be between 18 and 65 years old
Must not have
Not speaking English or Spanish
Under the age of 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after consented to the study.
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at the reasons why men don't finish their fertility evaluation, which is important to understand so that all aspects of infertility can be addressed in treatment. COVID-19 has made it especially hard for low-income communities to access medical care, so this trial is important for those affected by the pandemic.

Who is the study for?
This study is for English or Spanish speaking male partners of women undergoing infertility evaluations at Zuckerberg San Francisco General Hospital, who are recommended to have a semen analysis. Men must be over 18 years old and able to produce a semen sample.
What is being tested?
The trial is testing the use of mail-in semen analysis kits as part of the male infertility evaluation process, especially aimed at improving access in low-resourced settings affected by COVID-19.
What are the potential side effects?
Since this intervention involves only providing a semen sample using a kit, there are no direct medical side effects associated with it.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a male partner of a patient at Zuckerberg San Francisco General Hospital, advised to have a semen analysis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not speak English or Spanish.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three months after being consented to the study.
This trial's timeline: 3 weeks for screening, Varies for treatment, and three months after being consented to the study. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To compare the time to complete the semen analysis with in-clinic versus at-home testing.
Secondary study objectives
To compare barriers unique to completing an in-clinic versus at-home testing.
To compare satisfaction scores with in-clinic versus at-home testing.
To compare the time to initiating treatment after completing in-clinic versus at-home testing.
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: No in-clinic semen analysis testingExperimental Treatment1 Intervention
Men needing semen analysis for infertility work-up.
Group II: In-Clinic Semen Analysis TestingActive Control1 Intervention
Men needing semen analysis for infertility work-up.

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,887,890 Total Patients Enrolled
Yanett Anaya, M.D.Principal InvestigatorUniversity of California, San Francisco

Media Library

Mail-in semen analysis kit (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05205733 — N/A
Healthy Subjects Research Study Groups: In-Clinic Semen Analysis Testing, No in-clinic semen analysis testing
Healthy Subjects Clinical Trial 2023: Mail-in semen analysis kit Highlights & Side Effects. Trial Name: NCT05205733 — N/A
Mail-in semen analysis kit (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05205733 — N/A
~17 spots leftby Dec 2025